# Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis

> **NCT00390975** · PHASE4 · TERMINATED · sponsor: **Novartis** · enrollment: 40 (estimated)

## Conditions studied

- Gastroparesis
- Diabetes

## Interventions

- **DRUG:** Tegaserod

## Key facts

- **NCT ID:** NCT00390975
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** This study was terminated early as a result of regulatory action suspending tegaserod use in 2007
- **Last updated:** 2012-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390975, "Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00390975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*